摘要
Abstract
Objective To evaluate the clinical efficacy and safety of li-posomal prostaglandin E 1 ( Lipo PGE1 ) combined with fosinopril in the treatment of diabetic nephropathy with albuminuria .Methods Seventy patients of diabetic nephropathy were randomly divided into control group ( n=35 ) and treatment group ( n=35 ) .The control group was treated with oral administration of fosinopril 20 mg · d-1 , once daily for 14 d. On the basis of the treatment of control group , the treatment group was treated with intravenous injection of Lipo PGE 1 20 μg· d-1 , once daily for 14 d.The urine protein , 24 h urinary albumin excretion rate , serum creatinine, urine nitrogen, serum albumin, platelet average size, serum fibrinogen, D -dimer, clinical efficacy and adverse effects rate were compared between the two groups . Results The clinical efficacy of treatment group was 91.43%, significantly higher than that of control group 71.43%(P<0.05).The urine protein, 24 h urinary albumin ex-cretion rate , serum creatinine , urine nitrogen , platelet average size , serum fibrinogen and D -dimer of treatment group were significantly lower than those of control group ( P <0.05 ) .The serum albumin of treatment group were significantly higher than that in control group (P<0.05).The incidence of adverse drug reactions between two groupswere no significantly different(P>0.05).Conclusion Using Lipo PGE1 combined with fosinopril for the treatment of albuminuria patients with diabetic nephropathy can improve curative effect .关键词
糖尿病肾病/蛋白尿/前列地尔/福辛普利Key words
diabetic nephropathy/albuminuria/liposomal prostaglandin E 1/fosinopril分类
医药卫生
